Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, consultant physician, hematology department, Hospital Universitario de Salamanca, MD, PhD, discusses the TOURMALINE-MM1 trial in multiple myeloma.

The phase III trial investigated the impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) compared to placebo plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

The IRd combination resulted in a significant improvement in progression free survival (PFS) compated to the control arm, says Mateos.

The benefit was sustained across different groups of patients regardless of prior lines of therapy.